Literature DB >> 7022626

The porphyrias: an example of pharmacogenetic disease.

K E McColl, R Moore.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 7022626     DOI： 10.1177/003693308102600109

Source DB:  PubMed          Journal:  Scott Med J        ISSN： 0036-9330            Impact factor:   0.729


× No keyword cloud information.
  3 in total

1.  Studies in laboratory animals to assess the safety of anti-inflammatory agents in acute porphyria.

Authors:  K E McColl; G G Thompson; M R Moore
Journal:  Ann Rheum Dis       Date:  1987-07       Impact factor: 19.103

2.  Screening for latent acute intermittent porphyria: the value of measuring both leucocyte delta-aminolaevulinic acid synthase and erythrocyte uroporphyrinogen-1-synthase activities.

Authors:  K E McColl; M R Moore; G G Thompson; A Goldberg
Journal:  J Med Genet       Date:  1982-08       Impact factor: 6.318

3.  Safety of general anaesthesia and surgery in acute hepatic porphyria.

Authors:  S B Dover; L Plenderleith; M R Moore; K E McColl
Journal:  Gut       Date:  1994-08       Impact factor: 23.059
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.